Discovery of a dual-acting inhibitor of interleukin-1β and STATs for the treatment of inflammatory bowel disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discovery of a dual-acting inhibitor of interleukin-1β and STATs for the treatment of inflammatory bowel disease

Published:2024 Issue:1 Volume:15 Page:193-206
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Cai Haowei¹,Liu Zhuorong¹,Sun Ping¹,Zhou Yinghua¹,Yan Yuyun¹,Luo Yiming¹,Zhang Xiuxiu¹,Wu Ruiwen¹,Liang Xiangting¹,Wu Dan¹,Hu Wenhui¹,Yang Zhongjin¹^ORCID

Affiliation:

1. Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China

Abstract

Hybridization of active fragments led to the NLRP3-based dual inhibitor 10v, which exhibited potent inhibitory activity against the IL-1β and STAT pathway.

Funder

Guangzhou Municipal Science and Technology Project

National Natural Science Foundation of China

Government of Guangdong Province

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D3MD00451A

Reference28 articles.

1. Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries

2. Ulcerative colitis

3. Crohn's disease

4. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User’s Guide for Adult and Pediatric Gastroenterologists

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP